1. Search Result
Search Result
Results for "

fluoroquinolone

" in MCE Product Catalog:

72

Inhibitors & Agonists

10

Natural
Products

22

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-B0132B
    Norfloxacin (nicotinate)

    MK-0366 (nicotinate)

    Bacterial Antibiotic Infection
    Norfloxacin nicotinate (MK-0366 nicotinate) is a fluoroquinolones antibiotic, an adduct of Norfloxacin (NOR) and nicotinic acid. Norfloxacin nicotinate has been widely used for replacing NOR in animal husbandry and fishery industry. Norfloxacin nicotinate can induce innate immune response at a high concentration.
  • HY-A0147
    Grepafloxacin

    OPC-17116; dl-Grepafloxacin

    Antibiotic Bacterial Infection
    Grepafloxacin (OPC-17116) is an oral actively fluoroquinolone antibiotic with potent activity against community-acquired respiratory pathogens including Streptococcus pneumonia. Grepafloxacin has high tissue penetration and a promising pharmacodynamic profile.
  • HY-B0126
    Marbofloxacin

    Bacterial Antibiotic Infection
    Marbofloxacin is a third generation fluoroquinolone and orally active antimicrobial agent, which has a broad spectrum bactericidal activity and good efficacy. Marbofloxacin can be used for the research of infections by Gram-positive and Gram-negative bacteria and Mycoplasma.
  • HY-B0126A
    Marbofloxacin hydrochloride

    Bacterial Antibiotic Infection
    Marbofloxacin hydrochloride is a third generation fluoroquinolone and orally active antimicrobial agent, which has a broad spectrum bactericidal activity and good efficacy. Marbofloxacin hydrochloride can be used for the research of infections by Gram-positive and Gram-negative bacteria and Mycoplasma.
  • HY-B0395B
    Sitafloxacin monohydrate

    DU6859a monohydrate

    Bacterial Antibiotic Infection
    Sitafloxacin (DU6859a) monohydrate is a potent, orally active fluoroquinolone antibiotic. Sitafloxacin monohydrate shows antichlamydial activity and antibacterial activities against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin monohydrate can be used for the research of respiratory tract infection and urinary tract infection.
  • HY-B0395C
    Sitafloxacin hydrate

    DU6859a hydrate

    Bacterial Antibiotic Infection
    Sitafloxacin (DU6859a) hydrate is a potent, orally active fluoroquinolone antibiotic with in vitro activity against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin can be used for the research of respiratory tract infection and urinary tract infection.
  • HY-B0395A
    Sitafloxacin hydrochloride

    DU6859a hydrochloride

    Antibiotic Bacterial Infection
    Sitafloxacin (DU6859a) hydrochloride is a potent, orally active fluoroquinolone antibiotic. Sitafloxacin hydrochloride shows antichlamydial activity and antibacterial activities against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin hydrochloride can be used for the research of respiratory tract infection and urinary tract infection.
  • HY-B0395
    Sitafloxacin

    DU6859a

    Bacterial Antibiotic Infection
    Sitafloxacin (DU6859a) is a potent, orally active fluoroquinolone antibiotic. Sitafloxacin shows antichlamydial activity and antibacterial activities against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin can be used for the research of respiratory tract infection and urinary tract infection.
  • HY-139010
    Merafloxacin

    CI-934

    SARS-CoV Infection
    Merafloxacin (CI-934), a fluoroquinolone antibacterial agent, is a selective programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of beta coronaviruses. Merafloxacin exhibits in vitro activity against gram-positive and gram-negative bacteria.
  • HY-16745
    Lascufloxacin

    KRP-AM1977X

    Bacterial Infection
    Lascufloxacin (KRP-AM1977X) is a potent and orally active fluoroquinolone antibacterial agent. Lascufloxacin potently inhibits infections caused by various pathogens, including quinolone-resistant strains. Lascufloxacin has the potential for various infectious diseases treatment, including lower respiratory tract infections.
  • HY-B0159
    Balofloxacin

    Q-35

    Bacterial Antibiotic Infection
    Balofloxacin (Q-35) is an orally active fluoroquinolone antibiotic with broad-spectrum antibacterial activity against gram-negative, gram-positive, and anaerobic bacteria. Balofloxacin can be used for the research of respiratory, intestinal, and urinary tract infections.
  • HY-W011117
    Danofloxacin

    Bacterial DNA/RNA Synthesis Antibiotic Infection
    Danofloxacin is a third generation fluoroquinolone and orally active antimicrobial agent. Danofloxacin shows a broad spectrum of activity against most Gram-negative and Gram-positive bacteria, mycoplasma and chlamydia species, and plays an antimicrobial role by inhibition of bacterial DNA-gyrase. Danofloxacinh has the potential for respiratory diseases in cattle, swine, and chickens treatment.
  • HY-B0159A
    Balofloxacin dihydrate

    Q-35 dihydrate

    Bacterial Antibiotic Infection
    Balofloxacin dihydrate (Q-35 dihydrate) is an orally active fluoroquinolone antibiotic with broad-spectrum antibacterial activity against gram-negative, gram-positive, and anaerobic bacteria. Balofloxacin dihydrate can be used for the research of respiratory, intestinal, and urinary tract infections.
  • HY-B1802A
    Tosufloxacin tosylate hydrate

    A-61827 tosylate hydrate

    Bacterial Antibiotic Infection
    Tosufloxacin (tosylate hydrate) is a fluoroquinolone antibacterial agent.
  • HY-17028
    Besifloxacin Hydrochloride

    Bacterial Antibiotic Infection
    Besifloxacin hydrochloride is a fourth-generation fluoroquinolone antibiotic.
  • HY-B0724A
    Pazufloxacin mesylate

    T-3762; Pazufloxacin methanesulfonate; Pazufloxacin mesilate

    Bacterial Antibiotic Infection
    Pazufloxacin (T-3761) mesylate is a fluoroquinolone antibiotic.
  • HY-B0724B
    Pazufloxacin

    T3761

    Bacterial Antibiotic Infection
    Pazufloxacin (T-3761) is a fluoroquinolone antibiotic.
  • HY-U00389
    WQ3810

    KPI-10 free base

    Bacterial Infection
    WQ3810 is an orally active fluoroquinolone, with potent antibacterial activities.
  • HY-B0414
    Fleroxacin

    RO 23-6240; AM-833

    Bacterial Antibiotic Infection
    Fleroxacin (RO 23-6240) is a broad-spectrum antimicrobial fluoroquinolone.
  • HY-B0501
    Danofloxacin mesylate

    CP 76136-27

    Bacterial Antibiotic Infection
    Danofloxacin mesylate (CP 76136-27) is a fluoroquinolone antibacterial for veterinary use.
  • HY-U00214
    Ibafloxacine

    R835; S25930

    Bacterial Infection
    Ibafloxacine (R835) is a fluoroquinolone antibiotic agent that is developed exclusively for veterinary use.
  • HY-B0506
    Nadifloxacin

    OPC7251

    Bacterial Antibiotic Infection
    Nadifloxacin(OPC7251) is a topical fluoroquinolone antibiotic for the treatment of acne vulgaris.
  • HY-13451
    Finafloxacin

    Bacterial Infection
    Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments.
  • HY-B0915
    Orbifloxacin

    CP-104354

    Bacterial Antibiotic Infection
    Orbifloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic which is approved for use in dogs.
  • HY-B0308
    Sparfloxacin

    CI-978; AT-4140

    Bacterial Antibiotic Infection
    Sparfloxacin (CI-978) is a fluoroquinolone antibiotic, shows broad and potent antibacterial activity.
  • HY-B0724AS1
    ent-Pazufloxacin-d4 mesylate

    Bacterial Antibiotic Infection
    ent-Pazufloxacin-d4 mesylate is the deuterium labeled Pazufloxacin mesylate. Pazufloxacin (T-3761) mesylate is a fluoroquinolone antibiotic.
  • HY-B0501S
    Danofloxacin-d3 mesylate

    Bacterial Antibiotic Infection
    Danofloxacin-d3 mesylate is the deuterium labeled Danofloxacin mesylate. Danofloxacin mesylate (CP 76136-27) is a fluoroquinolone antibacterial for veterinary use.
  • HY-B0902A
    Rufloxacin hydrochloride

    MF-934 hydrochloride

    Bacterial Infection
    Rufloxacin hydrochloride (MF-934 hydrochloride) is a fluoroquinolone antibacterial, inhibits B-cell differentiation in human mononuclear cells, inhibits Topo.
  • HY-14762
    Besifloxacin

    Antibiotic Bacterial Infection
    Besifloxacin is a fluoroquinolone antimicrobial agent. Besifloxacin can inhibit cytokine production by monocytes. Besifloxacin has broad-spectrum antibacterial activity.
  • HY-135389
    Desmethyl Levofloxacin

    Drug Metabolite Infection
    Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
  • HY-B0356AS
    Ciprofloxacin-d8 hydrochloride hydrate

    Bay-09867-d8 hydrochloride hydrate

    Bacterial Antibiotic Infection
    Ciprofloxacin-d8 (Bay-09867-d8) hydrochloride monohydrate is the deuterium labeled Ciprofloxacin hydrochloride monohydrate. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-B0125
    Ofloxacin

    Hoe-280

    Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus Infection
    Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. Ofloxacin shows inhibitory activity against vaccinia virus (VV).
  • HY-B0356BS
    Ciprofloxacin-d8 hydrochloride monohydrate

    Bay-09867-d8 hydrochloride monohydrate

    Bacterial Antibiotic Infection
    Ciprofloxacin-d8 (Bay-09867-d8) hydrochloride monohydrate is the deuterium labeled Ciprofloxacin (hydrochloride monohydrate). Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-B0330S1
    (S)-Ofloxacin-d3

    Bacterial Antibiotic Infection
    (S)-Ofloxacin-d3 is the deuterium labeled Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
  • HY-B0724AS
    Pazufloxacin-d4 mesylate

    Bacterial Antibiotic Infection
    Pazufloxacin-d4 (T-3762-d4) mesylate is the deuterium labeled Pazufloxacin mesylate. Pazufloxacin (T-3761) mesylate is a fluoroquinolone antibiotic.
  • HY-B0506S
    Nadifloxacin-d9

    OPC7251-d9

    Bacterial Antibiotic Infection
    Nadifloxacin-d9 (OPC7251-d9) is the deuterium labeled Nadifloxacin. Nadifloxacin(OPC7251) is a topical fluoroquinolone antibiotic for the treatment of acne vulgaris.
  • HY-B0356S
    Ciprofloxacin-d8 hydrochloride

    Bay-09867-d8 hydrochloride

    Bacterial Antibiotic Infection
    Ciprofloxacin-d8 (Bay-09867-d8) hydrochloride is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-B0356S1
    Ciprofloxacin-d8

    Bay-09867-d8

    Bacterial Antibiotic Infection
    Ciprofloxacin-d8 (Bay-09867-d8) is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-B0330S
    Levofloxacin-d8

    (-)-Ofloxacin-d8

    Bacterial Antibiotic Infection
    Levofloxacin-d8 ((-)-Ofloxacin-d8) is the deuterium labeled Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
  • HY-16764
    Avarofloxacin

    JNJ-Q2

    Bacterial Infection Inflammation/Immunology
    Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Avarofloxacin (JNJ-Q2) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value. Avarofloxacin (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.
  • HY-B0125S1
    Ofloxacin-d8

    Bacterial Antibiotic Infection
    Ofloxacin-d8 (Hoe-280-d8) is the deuterium labeled Ofloxacin. Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase.
  • HY-116228
    Cadrofloxacin

    Caderofloxacin; CS-940

    Bacterial Infection
    Cadrofloxacin (Caderofloxacin; CS-940), a orally active fluoroquinolone, is effective against aerobic/anaerobic Gram-positive and Gram-negative bacteria. Cadrofloxacin can be used for the research of infectious diseases.
  • HY-135389S
    Desmethyl Levofloxacin-d8 hydrochloride

    Drug Metabolite Antibiotic Infection
    Desmethyl Levofloxacin-d8 hydrochloride is the deuterium labeled Desmethyl Levofloxacin. Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
  • HY-14814
    Delafloxacin

    RX-3341; WQ-3034; ABT492

    Bacterial Antibiotic Infection
    Delafloxacin (RX-3341; WQ-3034; ABT492) is a broad-spectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia.
  • HY-135389S1
    Desmethyl Levofloxacin-d8

    Drug Metabolite Antibiotic Infection
    Desmethyl Levofloxacin-d8 is deuterium labeled Desmethyl Levofloxacin. Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
  • HY-16035
    Alatrofloxacin

    DNA/RNA Synthesis Antibiotic Cancer
    Alatrofloxacin, the parenteral prodrug of Trovafloxacin, is a fluoronaphthyridone which contains an L-alanyl-L-alanyl salt. Alatrofloxacin functions similar to other fluoroquinolone antibiotics in that it not only has antibiotic activity to kill invading organisms by interfering with DNA synthesis, it possesses immunosuppressive activity.
  • HY-14814A
    Delafloxacin meglumine

    ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine

    Bacterial Antibiotic Infection
    Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine) is a broad-spectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia.
  • HY-116229
    Gemifloxacin

    SB-265805; LB20304

    Antibiotic Bacterial Infection
    Gemifloxacin, a fluoroquinolone, is a potent and orally active antipneumococcal agent. Gemifloxacin shows bactericidal activity against highly quinolone-resistant pneumococci.Gemifloxacin can be used for the research of respiratory infections, such as community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis (AECB).
  • HY-14814S
    Delafloxacin-d5

    RX-3341-d5; WQ-3034-d5; ABT492-d5

    Bacterial Antibiotic Infection
    Delafloxacin-d5 is deuterium labeled Delafloxacin. Delafloxacin (RX-3341; WQ-3034; ABT492) is a broad-spectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia.
  • HY-14776
    Quarfloxin

    CX-3543

    DNA/RNA Synthesis Cancer
    Quarfloxin (CX-3543), a fluoroquinolone derivative with antineoplastic activity, targets and inhibits RNA pol I activity, with IC50 values in the nanomolar range in neuroblastoma cells. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template.
  • HY-B0024
    Prulifloxacin

    NM441

    Bacterial Antibiotic Infection
    Prulifloxacin (NM441) is an orally active fluoroquinolone antibiotic with a broad spectrum of activity against Gram-positive and -negative bacteria. Prulifloxacin is a prodrug of a thiazeto-quinoline carboxylic acid derivative Ulifloxacin (NM394). Prulifloxacin has the potential for lower urinary tract infections and exacerbations of chronic bronchitis.
  • HY-B0126S
    Marbofloxacin-d8

    Bacterial Antibiotic Infection
    Marbofloxacin-d8 is the deuterium labeled Marbofloxacin. Marbofloxacin is a third generation fluoroquinolone and orally active antimicrobial agent, which has a broad spectrum bactericidal activity and good efficacy. Marbofloxacin can be used for the research of infections by Gram-positive and Gram-negative bacteria and Mycoplasma.
  • HY-B0356B
    Ciprofloxacin hydrochloride monohydrate

    Bay-09867 hydrochloride monohydrate

    Bacterial Antibiotic Infection Cancer
    Ciprofloxacin (Bay-09867) hydrochloride monohydrate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin hydrochloride monohydrate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin hydrochloride monohydrate has anti-proliferative activity and induces apoptosis. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-W011117S
    Danofloxacin-d3

    Bacterial DNA/RNA Synthesis Infection
    Danofloxacin-d3 is deuterium labeled Danofloxacin. Danofloxacin is a third generation fluoroquinolone and orally active antimicrobial agent. Danofloxacin shows a broad spectrum of activity against most Gram-negative and Gram-positive bacteria, mycoplasma and chlamydia species, and plays an antimicrobial role by inhibition of bacterial DNA-gyrase.
  • HY-B0356
    Ciprofloxacin

    Bay-09867

    Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species Cancer Infection
    Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-B0536A
    Clinafloxacin hydrochloride

    AM 1091 hydrochloride; CI 960 hydrochloride; PD127391 hydrochloride

    Bacterial Antibiotic Infection
    Clinafloxacin hydrochloride (AM 1091 hydrochloride) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro. Clinafloxacin hydrochloride is against DNA gyrase and topoisomerase IV of S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively.
  • HY-B0536
    Clinafloxacin

    AM-1091; CI-960; PD 127391

    Bacterial Antibiotic Infection
    Clinafloxacin (AM 1091) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro. Clinafloxacin is against DNA gyrase and topoisomerase IV of S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively.
  • HY-W040298
    Ciprofloxacin lactate

    Bay-09867 lactate

    Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species Cancer Infection
    Ciprofloxacin (Bay-09867) lactate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin lactate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin lactate has anti-proliferative activity and induces apoptosis. Ciprofloxacin lactate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-B0356A
    Ciprofloxacin monohydrochloride

    Bay-09867 monohydrochloride

    Topoisomerase Apoptosis Mitochondrial Metabolism Reactive Oxygen Species Antibiotic Bacterial Infection Cancer
    Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-10581A
    Gatifloxacin hydrochloride

    AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
  • HY-10581B
    Gatifloxacin mesylate

    AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
  • HY-B0024S
    Prulifloxacin-d8

    Bacterial Antibiotic Infection
    Prulifloxacin-d8 (NM441-d8) is the deuterium labeled Prulifloxacin. Prulifloxacin (NM441) is an orally active fluoroquinolone antibiotic with a broad spectrum of activity against Gram-positive and -negative bacteria. Prulifloxacin is a prodrug of a thiazeto-quinoline carboxylic acid derivative Ulifloxacin (NM394). Prulifloxacin has the potential for lower urinary tract infections and exacerbations of chronic bronchitis.
  • HY-123319A
    Antofloxacin

    Bacterial Infection
    Antofloxacin is a well tolerate, orally active and broad-spectrum 8-amino-fluoroquinolone with potent antibacterial activities. Antofloxacin shows superior antibacterial activity against gyrA mutation-positive H. pylori strains, especially in Asn87- mutated strains, compared to levofloxacin. Antofloxacin is a weak, reversible inhibitor of CYP1A2 for the treatment of infections caused by a diverse group of bacterial species.
  • HY-10581
    Gatifloxacin

    AM-1155; BMS-206584; PD135432

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml). Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
  • HY-123319
    Antofloxacin hydrochloride

    Bacterial Infection
    Antofloxacin hydrochloride is a well tolerate, orally active and broad-spectrum 8-amino-fluoroquinolone with potent antibacterial activities. Antofloxacin hydrochloride shows superior antibacterial activity against gyrA mutation-positive H. pylori strains, especially in Asn87- mutated strains, compared to levofloxacin. Antofloxacin hydrochloride is a weak, reversible inhibitor of CYP1A2 for the treatment of infections caused by a diverse group of bacterial species.
  • HY-10581C
    Gatifloxacin sesquihydrate

    AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate

    Bacterial Topoisomerase Antibiotic Infection Inflammation/Immunology
    Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.
  • HY-10581AS
    Gatifloxacin-d3 hydrochloride

    AM-1155-d3 hydrochloride; BMS-206584-d3 hydrochloride; PD135432-d3 hydrochloride

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin-d3 (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
  • HY-B0132S
    Norfloxacin-d5

    Bacterial Antibiotic Infection
    Norfloxacin-d5 is a deuterium labeled Norfloxacin. Norfloxacin is a fluoroquinolone antibiotic that inhibits the growth of Gram-positive and Gram-negative bacteria (MICs = 4 μg/mL and 1 μg/mL for S. aureus and P. aeruginosa, respectively). Norfloxacin also inhibits the growth S. pseudintermedius, S. aureus, E. coli, Pasturella, and S. canis isolates from dogs (mean MIC50s = 0.25 μg/mL, 1 μg/mL, 0.03 μg/mL, 1 μg/mL, and 1 μg/mL, respectively).
  • HY-B0268A
    Enoxacin hydrate

    Enoxacin sesquihydrate; AT-2266 hydrate; CI-919 hydrate

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Infection Cancer
    Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
  • HY-B0268
    Enoxacin

    AT 2266; CI 919

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Cancer Infection
    Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
  • HY-B0268S1
    Enoxacin-d8 hydrochloride

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Cancer Infection
    Enoxacin-d8 (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
  • HY-B0268S
    Enoxacin-d8

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Cancer Infection
    Enoxacin-d8 (AT 2266-d8) is the deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.